Increased survival of dopaminergic neurons
by rasagiline, a monoamine oxidase B inhibitor
by
Finberg JP, Takeshima T, Johnston JM, Commissiong JW
Department of Pharmacology,
Faculty of Medicine,
Technion, Haifa, Israel.
Neuroreport 1998 Mar 9; 9(4):703-7

ABSTRACT

Both deprenyl and rasagiline (R(+)-N-propargyl-1-aminoindane mesylate), at a concentration of 1-10 microM, increased survival in vitro of rat E14 mesencephalic dopaminergic neurons that had been primed with 10% serum for 12 h (p < 0.05). Rasagiline, but not deprenyl, also increased total neuronal (MAP2-positive) survival (p < 0.05) Under serum-free conditions, rasagiline, but not deprenyl, retained its neuroprotective action on dopaminergic neurones. GABAergic neurons were not affected by either deprenyl or rasagiline. Clorgyline, an MAO-A inhibitor, did not exert any of these effects. The protective action of rasagiline on dopaminergic neurons, even under stringent serum-free conditions, is striking, and warrants further investigation for a role in the treatment of Parkinson's disease.

MAO
GABA
TV3326
Piribedil
Selegiline
Levodopa
Dopamine
Rasagiline
Amphetamines
Propargylamines
Rasagiline: structure
Rasagiline: prospects
Rasagiline and the amines
Parkinson's disease and depression

Refs
and further reading

HOME
HedWeb
Nootropics
cocaine.wiki
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family